Arbutus Biopharma Corporation (ABUS) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -8.11M | -4.68M | -5.82M | -15.75M | -13.39M | -10.31M | -20.74M | -14.5M | -19.3M | -17.29M | -21.78M | -19.56M |
| Operating CF Margin % | -4.53% | -445.29% | -1099.62% | -146.65% | -759.13% | -655.34% | -1548.62% | -840.32% | -1259.46% | -806.15% | -467.67% | -420.53% |
| Operating CF Growth % | 39.44% | 54.63% | 71.95% | -8.58% | 30.6% | 40.35% | 4.81% | 25.84% | 29.32% | -1.78% | -16.54% | 3.62% |
| Net Income | 169.69M | -3.76M | -7.74M | 2.52M | -24.53M | -12.53M | -19.72M | -19.8M | -17.88M | -19.31M | -20.1M | -17.09M |
| Depreciation & Amortization | 11K | 1.03M | 11K | 11K | 330K | 333K | 336K | 356K | 355K | 359K | 369K | 342K |
| Stock-Based Compensation | 1.36M | 14.95M | 1.26M | 864K | 3.56M | 1.63M | 2.16M | 3.18M | 2.01M | 1.72M | 2.48M | 2.96M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -309K | -18.86M | -499K | -907K | 1.97M | 481K | -1.02M | -1M | -930K | -1.55M | -1.15M | -1.77M |
| Working Capital Changes | -178.87M | 1.96M | 1.15M | -18.24M | 5.27M | -229K | -2.5M | 2.76M | -2.86M | 1.49M | -3.38M | -4M |
| Change in Receivables | -177.58M | -149.21K | 120K | 157K | 1.23M | -801K | 159K | 372K | -363K | 395K | 443K | 50K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -985K | 846.28K | 0 | 0 | 4.54M | 0 | 0 | 0 | -2.02M | 0 | 0 | -848K |
| Cash from Investing | 2.2M | -1.36M | -10.02M | 15.61M | 11.35M | 13.41M | -11.99M | 9.83M | 11.69M | 22.23M | 10.43M | 1.44M |
| Capital Expenditures | 0 | 0 | 0 | 9K | 0 | -86K | 0 | -1K | -95K | 0 | -32K | -859K |
| CapEx % of Revenue | - | 0% | - | 0.08% | - | 5.46% | - | 0.06% | 6.2% | - | 0.69% | 18.47% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37.19M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 353K | 157.18M | 0 | 0 | 0 | 0 | 0 | 0 | -37.19M | 0 | 20K | 0 |
| Cash from Financing | 11.62M | 1.64M | 844K | 453K | 2.78M | 1.42M | 1.77M | 24.37M | 24.43M | 3.81M | 1.68M | 4.74M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 11.62M | 1.59M | 0 | 0 | 0 | -1K | 0 | 22.36M | 21.77M | 3.85M | 1.4M | 4.74M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 50.65K | 844K | 453K | 2.78M | 1.42M | 1.77M | 2.01M | 2.67M | -45K | 285K | 0 |
| Net Change in Cash | 5.7M | -4.4M | -15M | 336K | 746K | 4.48M | -30.94M | 19.69M | 16.82M | 8.75M | -9.67M | -13.38M |
| Free Cash Flow | -8.11M | -4.68M | -5.82M | -15.75M | -13.39M | -10.4M | -20.74M | -14.51M | -19.39M | -17.29M | -21.82M | -20.42M |
| FCF Margin % | -4.53% | -445.29% | -1099.62% | -146.65% | -759.13% | -660.8% | -1548.62% | -840.38% | -1265.67% | -806.15% | -468.36% | -439% |
| FCF Growth % | 39.44% | 55% | 71.95% | -8.58% | 30.94% | 39.85% | 4.95% | 28.96% | 29.28% | -0.98% | -16.15% | 0.42% |
| FCF per Share | -0.04 | -0.02 | -0.03 | -0.08 | -0.07 | -0.05 | -0.11 | -0.08 | -0.11 | -0.10 | -0.13 | -0.12 |
| FCF Conversion (FCF/Net Income) | -0.05x | 1.25x | 0.75x | -6.24x | 0.55x | 0.82x | 1.05x | 0.73x | 1.08x | 0.90x | 1.08x | 1.14x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |